The BRAIN study randomized 176 treatment-naïve patients with ≥3 BrM from EGFRm NSCLC to receive first-generation EGFR inhibitor icotinib, or WBRT (30 Gy in 10 fractions) with concurrent or sequential chemotherapy.28 The study’s primary endpoint was intracranial progression-free survival (PFS; IC-PFS) by RECIST criteria. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.